Unknown PHASE2 INTERVENTIONAL 2-arm NCT02280070

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301).

Sponsor: Clinical Research Support Center Kyush

Conditions Rectal Cancer

Interventions 5-FU Adverse event BW and height Biomarker Contrasting CT Creatinine clearance Endoscopy HBs antibody and HBc antibody HBs antigen and HCV antibody L-OHP (130mg/m2) L-OHP (85 mg/m2) Laboratory test Medical history and physical examination Performance status S-1 l-LV

Updated 6 times since 2017 Last updated: Oct 29, 2014 Started: Sep 30, 2013 Primary completion: Aug 31, 2018 Completion: Aug 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rectal Cancer, this trial is ongoing. The trial is conducted by Clinical Research Support Center Kyush and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Sep 2020 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinical Research Support Center Kyush

Data source: Clinical Research Support Center Kyush

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fukuoka, Japan
• Kurume, Japan